Pediatric Eye Disease Investigator Group C02 Pediatric cataract surgery registry
Pediatric Eye Disease Investigator Group CITS Convergence insufficiency treatment study
Pediatric Eye Disease Investigator Group IXT1 Randomized trial of bilateral lateral rectus recession versus unilateral recess-resect for intermittent exotropia
Pediatric Eye Disease Investigator Group IXT2 Randomized clinical trial of observation versus occlusion therapy for intermittent exotropia
Pediatric Eye Disease Investigator Group IXT3 A pilot randomization clinical trial of overminus therapy for intermittent exotropia
Pediatric Eye Disease Investigator Group E02 Esotropia treatment with Botox data collection
GoCheck Prospective Evaluation of mobile phone photography application as a vision screening tool in children
Pediatric Eye Disease Investigator Group ATS18 Study of binocular computer activities for treatment of amblyopia
Pediatric Eye Disease Investigator Group protocol HTS1 Glasses vs observation for moderate hyperopia in young children
Pediatric Eye Disease Investigator Group protocol ATS17 A Randomized trial of Levodopa as treatment for residual amblyopia
Pediatric Eye Disease Investigator Group protocol CITS Convergence insufficiency treatment study
Pediatric Eye Disease Investigator Group protocol HTS1 Glasses vs observation for moderate hyperopia in young children
Pediatric Eye Disease Investigator Group protocol A16 Augmenting Atropine Treatment for Amblyopia
Pediatric Eye Disease Investigator Group protocol A15 – Increasing Patching for Amblyopia
Pediatric Eye Disease Investigator Group protocol A14 A pilot study to evaluate Levodopa as treatment for residual amblyopia in 8 to 17 year olds
Pediatric Eye Disease Investigator Group protocol A13 An observational study of optical correction for strabismic amblyopia in children 3 to <7 years old
Pediatric Eye Disease Investigator Group protocol A12 A Randomized Trial Comparing Patching with Active Vision Therapy to Patching with Control Vision Therapy for Amblyopia in Children 7 to < 13 Years Old
Pediatric Eye Disease Investigator Group protocol A11 A Randomized Trial to Evaluate 8 Hours of Daily Patching Plus Daily Atropine for Residual Amblyopia in Children 3 to <8 Years Old
Pediatric Eye Disease Investigator Group protocol A10 A Randomized Trial of Full-time Bangerter Filters versus Part-time Daily Patching for the Treatment of Moderate Amblyopia in Children
Pediatric Eye Disease Investigator Group protocol ATS9 A Randomized Trial Comparing Patching Versus Atropine for Amblyopia in 7 to <13 Year Olds
Pediatric Eye Disease Investigator Group protocol ATS8 A Randomized Trial Comparing Atropine to Atropine Plus a Reduced-Plus Lens for the Sound Eye as Treatments for Amblyopia in Children 3 to <7
Pediatric Eye Disease Investigator Group protocol ATS7 Bilateral Refractive Amblyopia Treatment Study
Pediatric Eye Disease Investigator Group protocol ATS6 A Randomized Trial to Compare Near Versus Distance Activities While Patching for Amblyopia
Pediatric Eye Disease Investigator Group protocol ATS5 Treatment of Anisometropic Amblyopia in Children with Refractive Correction
Pediatric Eye Disease Investigator Group protocol ATS4 A Randomized Trial of Atropine Regimens for Treatment of Moderate Amblyopia in Children
Pediatric Eye Disease Investigator Group protocol ATS3 A prospective, pilot study of treatment of amblyopia in children 10 to <18 years old
Pediatric Eye Disease Investigator Group protocol ATS2A A randomized trial comparing part-time vs. full-time patching for severe amblyopia
Pediatric Eye Disease Investigator Group protocol ATS2B A randomized trial comparing part-time versus minimal-time patching for moderate amblyopia
Pediatric Eye Disease Investigator Group protocol ATS2C Risk of amblyopia recurrence after cessation of treatment
Pediatric Eye Disease Investigator Group protocol ATS1 A randomized trial of atropine vs. patching for treatment of moderate amblyopia in children
Pediatric Eye Disease Investigator Group protocol NLD 1 A Prospective Study of Primary Surgical Treatment of Nasolacrimal Duct Obstruction in Children Less Than Four Years Old
Pediatric Eye Disease Investigator Group protocol NLD2 A Prospective Study of Surgical Procedures for the Treatment of Persistent Nasolacrimal Duct Obstruction in Children < 4 years old
Pediatric Eye Disease Investigator Group protocol NLD3 A Randomized Trial Comparing Immediate Probing in an Office Setting with Deferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to <10 Months Old
Pediatric Eye Disease Investigator Group protocol ETS1 An Observational Study of Infantile, Acquired Non-accommodative, and Acquired Partially-accommodative Esotropia
Pediatric Eye Disease Investigator Group protocol CCT A Prospective Study of Central Corneal Thickness in Children Less than 18 Years old
Pediatric Eye Disease Investigator Group protocol COMET2 A randomized trial of the effect of progressive addition lenses versus single vision lenses on low myopia associated with large accommodative lags and near esophoria in children
Pediatric Eye Disease Investigator Group protocol X01 Correction of Refractive Error for Amblyopia Study
Bausch & Lomb A randomized, double-masked, active-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of topical besifloxacin ophthalmic suspension, 0.6% compared with gatifloxacin, 0.3% ophthalmic solution for the treatment of presumed bacterial conjunctivitis in subjects from birth to 31 days of age
Bausch & Lomb A Clinical and Efficacy Evaluation of Zylet (Ioteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) compared to Lotemax (Ioteprednol etabonate ophthalmic suspension 0.5%), Tobramycin Ophthalmic Solution USP, 0.3%, and the Vehicle of Zylet for the Treatment of Blepharoconjunctivitis in Pediatric Subjects
Bausch & Lomb Study #459 A Safety and Efficacy Study of Zylet® (Ioteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension) Compared to Vehicle in the Management of Lid Inflammation in Pediatric Subjects
Alcon Evaluation of ESBa105 in the persistent relief of ocular discomfort in patients with severe dry eye
Inspire A multi-center, parallel-group, double-masked, randomized, placebo-controlled study of the effects of diquafosol tetrasodium ophthalmic solution, 2% in subjects with dry eye disease and a central corneal staining score of 3 (NEI Scale)
Alcon A Randomize, Double-Masked and Efficacy Study of FID #109980 Compared to FID #110656 in the Treatment of Dry Eye
Lexitas Dry Eye Study A multi-center, double-masked, randomized, controlled, efficacy and safety study of EBI-005 5 mg/mL topical ophthalmic solution versus vehicle control in subjets with moderate to severe dry eye disease
TearScience LF-001 Randomized Clinical Trial for Treatment of Meibomian Gland Dysfunction and Evaporation Dry Eye
Bausch & Lomb A study to evaluate the clinical and microbial efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID compared to vehicle in the treatment of bacterial conjunctivitis
Bausch & Lomb Study A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis
Eli Lilly Study of the possible association between the use of PDE5 inhibitors and the risk of acute nonarteritic anterior ischemic optic neuropathy (NAION)
Pfizer study A1481259 Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential “Trigger Factor” for Acute NAION
Bausch & Lomb A randomized, multicenter, double-masked, parallel-group, clinical safety and efficacy evaluation of loteprednol etabonate ophthalmic gel, 0.5% versus vehicle for the treatment of inflammation and pain following cataract surgery
Bausch & Lomb A phase 3, multi-center, double-masked, vehicle-controlled, randomized, parallel-group study to assess loteprednol etabonate ophthalmic gel, 0.38% versus vehicle gel for the treatment of ocular inflammation and pain following cataract surgery
Inspire Study Phase IV. A Multi-Center, Open-Label, Registry of Epinastine HCl Ophthalmic Solution, 0.05% (Elestat) in Subjects with History and Current Complaint of Ocular Allergy Symptom
A clinical evaluation of Juvederm Ultra Injectable Gel for the correction of moderate to severe facial wrinkles and folds ( Silbert)
Study utilizing the platelet factor 4 – fluorescein method for examination of endothelial cell surface and platelet surface proteoglycans
Study Developing a platelet factor 4 – fluorescein probe and applied it to the examination of the content and distribution of cell surface proteoglycans in cultures of several types of cells